Vol. 1 No. 5 (2026), Articles
Vol. 1 No. 5 (2026)

Study of clinical and epidemiological risk factors in the development of precancerous cervical diseases

Articles
Published 2026-05-24
Zokhidova Begoyim
Master's Student, Department of General Oncology, Andijan State Medical Institute
PDF

Keywords

cervical intraepithelial neoplasia; HPV persistence; precancerous lesions; epidemiological risk stratification; screening adherence; oncological prevention

How to Cite

Zokhidova Begoyim. (2026). Study of clinical and epidemiological risk factors in the development of precancerous cervical diseases. INTERNATIONAL CONFERENCE ON MODERN RESEARCH AND SCIENTIFIC INNOVATION, 1(5), 213-217. https://doi.org/10.5281/zenodo.20364585
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Precancerous cervical lesions occupy a decisive position in the carcinogenic continuum, where early identification of modifiable risk determinants can substantially redirect disease trajectory. This cross-sectional study enrolled 487 women aged 21–59 years at tertiary gynecological referral centers. Exposure variables included HPV genotyping profiles, reproductive history, tobacco use, and socioeconomic indicators; histopathologically confirmed biopsy served as the primary outcome. Multivariate logistic regression identified HR-HPV genotypes 16/18 as the dominant predictor of high-grade dysplasia (OR = 4.7; 95% CI: 2.9–7.6; p < 0.001). Persistent viral carriage exceeding 24 months, tobacco smoking (OR = 2.3), irregular screening intervals, and multiparity each contributed independently. A four-variable composite model achieved AUC = 0.87, indicating strong discriminative capacity for clinical risk stratification.

PDF

References

1. Arbyn M, et al. Estimates of incidence and mortality of cervical cancer in 2018. Lancet Glob Health. 2020;8(2):e191–203.

2. Schiffman M, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2021;7(1):82.

3. Wentzensen N, et al. HPV screening with p16/Ki-67 dual stain triage. JAMA Intern Med. 2021;181(7):881–8.

4. Gage JC, et al. Long-term CIN 3+ risk by HPV genotype and persistence. J Natl Cancer Inst. 2022;114(3):405–13.

5. Katki HA, et al. Five-year risks of CIN 3+ with HPV-positive and HPV-negative results. J Natl Cancer Inst. 2021;113(9):1188–95.

6. Khan MJ, et al. Elevated 10-year risk with HPV types 16 or 18. J Natl Cancer Inst. 2022;114(8):1102–9.

7. Rodriguez AC, et al. Rapid HPV clearance and implications for persistent infection focus. J Natl Cancer Inst. 2020;112(5):515–23.

8. Moscicki AB, et al. Updating the natural history of HPV and anogenital cancers. Vaccine. 2021;39(S3):A24–31.

9. Bosch FX, et al. Epidemiology and natural history of HPV and cervical neoplasia. Vaccine. 2021;39(S1):A1–12.

10. Drolet M, et al. Population-level impact of HPV vaccination: meta-analysis. Lancet. 2020;396(10250):525–36.

11. Bruni L, et al. HPV vaccination and national immunization coverage 2010–2022. Prev Med. 2023;174:107637.

12. Wright TC, et al. Clinical performance of the Onclarity HPV assay. J Clin Microbiol. 2022;60(4):e02156–21.

13. Bouvard V, et al. The IARC perspective on cervical cancer screening. N Engl J Med. 2021;385(20):1908–18.

14. Canfell K, et al. HPV vaccination and screening strategies: comparative modeling. Lancet. 2020;396(10250):595–606.

15. Smith JS, et al. Age-specific HPV prevalence in women: global review. J Adolesc Health. 2021;68(4S):S23–31.